Welcome to LookChem.com Sign In|Join Free

CAS

  • or

15307-86-5

Post Buying Request

15307-86-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

15307-86-5 Usage

Application in Particular Diseases

In Osteoarthritis: Topical diclofenac in a dimethyl sulfoxide carrier (Pennsaid) is a safe and effective treatment for Osteoarthritis pain. It is thought to act primarily by local inhibition of COX-2 enzymes.

Uses

Different sources of media describe the Uses of 15307-86-5 differently. You can refer to the following data:
1. Diclofenac possesses all of the properties unique to the series of propionic acid drugs, yet in terms of anti-inflammatory and analgesic strength it exceeds that of aspirin, analgin, and ibuprofen. It is used in acute rheumatism, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, arthrosis, back pain, neuralgia, and myalgia. It rarely causes side effects. The most common synonym is voltaren.
2. prostaglandin synthetic inhibitor

Indications

Diclofenac (Voltaren, Cataflam) is approved for use in rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, dysmenorrhea, and topically for the treatment treatment of ocular inflammation and actinic keratosis. Diclofenac exhibits approximately equal selectivity for COX-1 and COX-2. The most common adverse reactions are GI disturbances and headache.A reversible elevation of serum transaminases occurs in 15% of patients.

Therapeutic Function

Antiinflammatory

Biological Functions

Diclofenac (Voltaren) is a phenylacetic acid derivative that is a potent inhibitor of COX and that has analgesic, antiinflammatory, and antipyretic effects. Its use is accompanied by side effects similar to those of other NSAIDs. Indications for the drug include rheumatoid arthritis, osteoarthritis, and ophthalmic inflammation (use of an ophthalmic preparation).

Mechanism of action

Diclofenac is unique among the NSAIDs in that it possesses three possible mechanisms of action: 1) inhibition of the arachidonic acid cyclooxygenase system (3 to 1,000 times more potent than other NSAIDs on a molar basis), resulting in a decreased production of prostaglandins and thromboxanes; 2) inhibition of the lipoxygenase pathway, resulting in decreased production of leukotrienes, particularly the pro-inflammatory LKB4; and 3) inhibition of arachidonic acid release and stimulation of its reuptake, resulting in a reduction of arachidonic acid availability.

Pharmacokinetics

Diclofenac is rapidly and completely (~100%) absorbed on oral administration, with peak plasma levels being reached within 1.5 to 2.5 hours. The free acid (pKa = 4.0) is highly bound to serum proteins (99.5%), primarily albumin. Only 50 to 60% of an oral dose is bioavailable because of extensive hepatic metabolism.

Clinical Use

Diclofenac is synthesized from N-phenyl-2,6-dichloroaniline. It is available in 120 different countries and, perhaps, is the most widely used NSAID in the world. It was introduced in the United States in 1989 but was first marketed in Japan in 1974. It ranks among the top prescription drugs in the United States. Diclofenac possesses structural characteristics of both arylalkanoic acid and the anthranilic acid classes of anti-inflammatory drugs, and it displays anti-inflammatory, analgetic, and antipyretic properties.

Synthesis

Diclofenac, 2-[(2,6-dichlorophenyl)-amino]-phenylacetic acid (3.2.42), is synthesized from 2-chlorobenzoic acid and 2,6-dichloroaniline. The reaction of these in the presence of sodium hydroxide and copper gives N-(2,6-dichlorophenyl)anthranylic acid (3.2.38), the carboxylic group of which undergoes reduction by lithium aluminum hydride. The resulting 2-[(2,6-dicholorphenyl)-amino]-benzyl alcohol (3.2.39) undergoes further chlorination by thionyl chloride into 2-[(2,6-dichlorophenyl)-amino]-benzylchloride (3.2.40) and further, upon reaction with sodium cyanide converts into 2-[(2,6-dicholorophenyl)-amino]benzyl cyanide (3.2.41). Hydrolysis of the nitrile group leads to diclofenac (3.2.42) [107,108].

Metabolism

Four major metabolites resulting from aromatic hydroxylation have been identified. The major metabolite via CYP3A4 is the 4′-hydroxy derivative and accounts for 20 to 30% of the dose excreted, whereas the 5-hydroxy, 3′-hydroxy, and 4′,5-dihydroxy metabolites via CYP2C9 account for 10 to 20% of the excreted dose. The remaining drug is excreted in the form of sulfate conjugates. Although the major metabolite is much less active than the parent compound, it may exhibit significant biological activity, because it accounts for 30 to 40% of all of the metabolic products.

Check Digit Verification of cas no

The CAS Registry Mumber 15307-86-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,3,0 and 7 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 15307-86:
(7*1)+(6*5)+(5*3)+(4*0)+(3*7)+(2*8)+(1*6)=95
95 % 10 = 5
So 15307-86-5 is a valid CAS Registry Number.
InChI:InChI=1/C14H9Cl2NO/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(17)18/h1-7H,8H2

15307-86-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (D3748)  2-(2,6-Dichloroanilino)phenylacetic Acid  >98.0%(GC)(T)

  • 15307-86-5

  • 25g

  • 940.00CNY

  • Detail

15307-86-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name diclofenac

1.2 Other means of identification

Product number -
Other names 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:15307-86-5 SDS

15307-86-5Synthetic route

[2-(2,6-dichloro-phenylamino)-phenyl]-acetic acid diethylcarbamoylmethylcarbamoyloxymethyl ester
934548-15-9

[2-(2,6-dichloro-phenylamino)-phenyl]-acetic acid diethylcarbamoylmethylcarbamoyloxymethyl ester

A

2-amino-N,N-diethylacetamide
34105-57-2

2-amino-N,N-diethylacetamide

B

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With human plasma In phosphate buffer at 37℃; pH=7.4;A n/a
B 100%
[2-(2,6-dichloro-phenylamino)-phenyl]-acetic acid 1-diethylcarbamoyl-2-phenyl-ethylcarbamoyloxymethyl ester
934548-16-0

[2-(2,6-dichloro-phenylamino)-phenyl]-acetic acid 1-diethylcarbamoyl-2-phenyl-ethylcarbamoyloxymethyl ester

A

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

B

N-(phenylalanyl)-N,N-diethylamine
40847-09-4

N-(phenylalanyl)-N,N-diethylamine

Conditions
ConditionsYield
With human plasma In phosphate buffer at 37℃; pH=7.4;A 100%
B n/a
diclofenac sodium
15307-79-6

diclofenac sodium

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With hydrogenchloride In water; acetone at 20 - 45℃; for 3h; pH=1.4 - 1.6; Solvent;99%
With hydrogenchloride In water Cooling with ice;90%
With hydrogenchloride In water at 0 - 20℃;70%
2,6-Dichlorophenol
87-65-0

2,6-Dichlorophenol

methyl 2-(2-(2-bromopropionamido)phenyl)acetate

methyl 2-(2-(2-bromopropionamido)phenyl)acetate

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With potassium hydroxide In dimethyl sulfoxide at 60 - 100℃; for 8h; Temperature; Reagent/catalyst;95%
N,N-dimethyl-o-(2,6-dichloroanilino)phenylacetamide
21789-06-0

N,N-dimethyl-o-(2,6-dichloroanilino)phenylacetamide

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With potassium hydroxide In ethanol; water92.9%
2-[(2,6-dichlorophenyl)-N-benzylamino]-phenylacetic acid
70690-44-7

2-[(2,6-dichlorophenyl)-N-benzylamino]-phenylacetic acid

water
7732-18-5

water

1,2-dichloro-benzene
95-50-1

1,2-dichloro-benzene

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
In tetrahydrofuran; hexane; toluene91.2%
2-<(2,6-dichlorophenyl)amino>-α-(methylthio)phenylacetic acid
83281-95-2

2-<(2,6-dichlorophenyl)amino>-α-(methylthio)phenylacetic acid

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With nickel In ethanol Heating;85%
1-(2,6-dichlorophenyl)indolin-2-one
15362-40-0

1-(2,6-dichlorophenyl)indolin-2-one

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
In hydrogenchloride; toluene liquid HCl;84.4%
Naprelan
26159-34-2

Naprelan

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With hydrogenchloride In water at 20℃;82.2%
ortho-bromophenylacetic acid
18698-97-0

ortho-bromophenylacetic acid

2,6-Dichloroaniline
608-31-1

2,6-Dichloroaniline

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With D-myo-inositol; copper; caesium carbonate In water at 100℃; for 30h;82%
2'-chloro-benzeneacetic acid
2444-36-2

2'-chloro-benzeneacetic acid

2,6-Dichloroaniline
608-31-1

2,6-Dichloroaniline

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With copper(l) iodide; potassium carbonate; potassium iodide In 1,4-dioxane at 130 - 150℃; for 7h; Concentration; Solvent; Inert atmosphere;80%
With copper(l) iodide; potassium carbonate; potassium iodide In N,N-dimethyl-formamide at 165℃; for 12h; Ullmann Condensation; Sealed tube;34%
With copper(I) chloride; potassium carbonate; potassium iodide In N,N-dimethyl-formamide; xylene at 150 - 152℃; for 5h;
rhodium(III) chloride

rhodium(III) chloride

o-(N-allyl-2,6-dichloroanilino)phenylacetic acid
75294-57-4

o-(N-allyl-2,6-dichloroanilino)phenylacetic acid

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
In 1,2-dimethoxyethane; water; benzene72%
ortho-bromophenylacetic acid
18698-97-0

ortho-bromophenylacetic acid

2,6-Dichloroaniline
608-31-1

2,6-Dichloroaniline

diethylene glycol
111-46-6

diethylene glycol

A

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

B

C12H16O5

C12H16O5

Conditions
ConditionsYield
With L-2-O-methyl-chiro-inositol; copper(II) acetate monohydrate; potassium carbonate at 110℃; for 12h; Inert atmosphere;A 72%
B 17%
2-(2-iodophenyl)acetonitrile
40400-15-5

2-(2-iodophenyl)acetonitrile

2,6-Dichloroaniline
608-31-1

2,6-Dichloroaniline

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
Stage #1: 2-(2-iodophenyl)acetonitrile With potassium hydroxide In ethanol at 80℃; for 12h; Inert atmosphere; Sealed tube;
Stage #2: 2,6-Dichloroaniline With copper(l) iodide; potassium carbonate In toluene at 100℃; for 12h; Inert atmosphere; Sealed tube;
70%
potassium 2-iodophenylacetate
100754-92-5

potassium 2-iodophenylacetate

2,6-Dichloroaniline
608-31-1

2,6-Dichloroaniline

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With 1-methyl-pyrrolidin-2-one; copper(l) iodide; potassium carbonate at 100℃; Ullmann coupling;61%
2-<(2,6-Dichlorphenacyl)amino>phenylessigsaeure-2-oxopropylester
137138-22-8

2-<(2,6-Dichlorphenacyl)amino>phenylessigsaeure-2-oxopropylester

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With buffer pH 8.0 In 1,4-dioxane; acetonitrile at 57℃; half-life time of hydrolysis at different pH;
2-(4-morpholino)ethyl<(o-2,6 dichlorophenylanilino)phenyl acetate> hydrochloride

2-(4-morpholino)ethyl<(o-2,6 dichlorophenylanilino)phenyl acetate> hydrochloride

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
at 37℃; Rate constant; t1/2, simulated gastric fluid, rate plasma, further reagents, temperatures;
[2-(2,6-Dichloro-phenylamino)-phenyl]-acetic acid 3-morpholin-4-yl-propyl ester; hydrochloride

[2-(2,6-Dichloro-phenylamino)-phenyl]-acetic acid 3-morpholin-4-yl-propyl ester; hydrochloride

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
at 37℃; Rate constant; t1/2, simulated gastric fluid, rate plasma, further reagents;
[2-(2,6-Dichloro-phenylamino)-phenyl]-acetic acid 4-morpholin-4-yl-butyl ester; hydrochloride

[2-(2,6-Dichloro-phenylamino)-phenyl]-acetic acid 4-morpholin-4-yl-butyl ester; hydrochloride

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
at 37℃; Rate constant; t1/2, simulated gastric fluid, rate plasma, further reagents;
[2-(2,6-dichloro-phenylamino)-phenyl]-acetic acid (benzoyl-ethoxycarbonylmethyl-amino)-methyl ester

[2-(2,6-dichloro-phenylamino)-phenyl]-acetic acid (benzoyl-ethoxycarbonylmethyl-amino)-methyl ester

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With NADPH-generating system; rat liver homogenate at 37℃; Enzyme kinetics; Hydrolysis; Enzymatic reaction;
diclofenac sodium
15307-79-6

diclofenac sodium

A

2-oxoindole
59-48-3

2-oxoindole

B

2,6-Dichlorophenol
87-65-0

2,6-Dichlorophenol

C

1-(2,6-dichlorophenyl)indolin-2-one
15362-40-0

1-(2,6-dichlorophenyl)indolin-2-one

D

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
In phosphate buffer at 45℃; Kinetics; Thermodynamic data; Further Variations:; pH-values; Temperatures;
aceclofenac
89796-99-6

aceclofenac

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With sodium hydroxide for 3h; Heating;
N-phenyl-2,6-dichloroaniline
15307-93-4

N-phenyl-2,6-dichloroaniline

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: benzene / 6 h / Heating
2: 91 percent / m-chloroperbenzoic acid / CH2Cl2 / 1 h / Ambient temperature
3: 84 percent / p-toluenesulfonic acid / benzene / 0.5 h / Heating
4: 91 percent / 2N NaOH / ethanol / 48 h / Heating
5: 85 percent / Raney nickel / ethanol / Heating
View Scheme
Multi-step reaction with 5 steps
1: benzene / 6 h / Heating
2: N-chlorosuccinimide / CCl4 / 1 h / Ambient temperature
3: SnCl4 / CCl4 / 0.83 h / Ambient temperature
4: 91 percent / 2N NaOH / ethanol / 48 h / Heating
5: 85 percent / Raney nickel / ethanol / Heating
View Scheme
N-(2,6-dichlorophenyl)-α-(methylthio)acetanilide
83281-93-0

N-(2,6-dichlorophenyl)-α-(methylthio)acetanilide

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 91 percent / m-chloroperbenzoic acid / CH2Cl2 / 1 h / Ambient temperature
2: 84 percent / p-toluenesulfonic acid / benzene / 0.5 h / Heating
3: 91 percent / 2N NaOH / ethanol / 48 h / Heating
4: 85 percent / Raney nickel / ethanol / Heating
View Scheme
Multi-step reaction with 4 steps
1: N-chlorosuccinimide / CCl4 / 1 h / Ambient temperature
2: SnCl4 / CCl4 / 0.83 h / Ambient temperature
3: 91 percent / 2N NaOH / ethanol / 48 h / Heating
4: 85 percent / Raney nickel / ethanol / Heating
View Scheme
1-(2,6-dichlorophenyl)-3-(methylthio)oxindole
83281-94-1

1-(2,6-dichlorophenyl)-3-(methylthio)oxindole

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 91 percent / 2N NaOH / ethanol / 48 h / Heating
2: 85 percent / Raney nickel / ethanol / Heating
View Scheme
N-(2,6-dichlorophenyl)-α-(methylsulfinyl)acetanilide
83281-96-3

N-(2,6-dichlorophenyl)-α-(methylsulfinyl)acetanilide

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 84 percent / p-toluenesulfonic acid / benzene / 0.5 h / Heating
2: 91 percent / 2N NaOH / ethanol / 48 h / Heating
3: 85 percent / Raney nickel / ethanol / Heating
View Scheme
α-chloro-N-(2,6-dichlorophenyl)-α-(methylthio)acetanilide

α-chloro-N-(2,6-dichlorophenyl)-α-(methylthio)acetanilide

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: SnCl4 / CCl4 / 0.83 h / Ambient temperature
2: 91 percent / 2N NaOH / ethanol / 48 h / Heating
3: 85 percent / Raney nickel / ethanol / Heating
View Scheme
4-((3,3-dimethylbutoxy)carbonyloxy)benzyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate
1224508-84-2

4-((3,3-dimethylbutoxy)carbonyloxy)benzyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

Conditions
ConditionsYield
With water at 37℃; pH=7.4; Kinetics;
bromoacetic acid tert-butyl ester
5292-43-3

bromoacetic acid tert-butyl ester

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

2-((2,6-dichlorophenyl)amino)phenylacetoxyacetic acid tert-butyl ester
139272-68-7

2-((2,6-dichlorophenyl)amino)phenylacetoxyacetic acid tert-butyl ester

Conditions
ConditionsYield
With sodium hydrogencarbonate In DMF (N,N-dimethyl-formamide) at 20℃;100%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

(+)-O-Demethyltramadol
144830-14-8

(+)-O-Demethyltramadol

(+)-O-desmethyl-tramadol diclofenac salt

(+)-O-desmethyl-tramadol diclofenac salt

Conditions
ConditionsYield
With water In acetonitrile at 20℃; under 760.051 Torr; Product distribution / selectivity;100%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

(±)-cis-2-[(dimethylamino)methyl]-1-(3-hydroxyphenyl)cyclohexanol
73986-53-5, 80456-81-1, 144830-14-8, 144830-15-9

(±)-cis-2-[(dimethylamino)methyl]-1-(3-hydroxyphenyl)cyclohexanol

(rac)-O-desmethyl-tramadol diclofenac salt

(rac)-O-desmethyl-tramadol diclofenac salt

Conditions
ConditionsYield
In isopropyl alcohol at 20℃; Product distribution / selectivity;100%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

O-desmethyltramadol
73986-53-5

O-desmethyltramadol

O-desmethyl-tramadol-diclofenac

O-desmethyl-tramadol-diclofenac

Conditions
ConditionsYield
In isopropyl alcohol at 20℃; Product distribution / selectivity;100%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

1-Adamantanamine
768-94-5

1-Adamantanamine

C10H17N*C14H11Cl2NO2

C10H17N*C14H11Cl2NO2

Conditions
ConditionsYield
In methanol at 20℃;100%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

2,2'-dimethyl-[1,1'-biphenyl]iodonium trifluoromethanesulfonate salt

2,2'-dimethyl-[1,1'-biphenyl]iodonium trifluoromethanesulfonate salt

C28H22Cl2INO2

C28H22Cl2INO2

Conditions
ConditionsYield
With copper diacetate; sodium carbonate; (3aR,3a'R,8aS,8a'S)-2,2'-(propane-2,2-diyl)bis(8,8a-dihydro-3aH-indeno[1,2-d]oxazole) In dichloromethane; water at 30℃; for 12h; enantioselective reaction;99%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

C10H20N2O2S

C10H20N2O2S

C24H29Cl2N3O3S

C24H29Cl2N3O3S

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 0℃; for 0.5h; Acylation;98%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

(2E)-3-phenyl-2-propen-1-ol
4407-36-7

(2E)-3-phenyl-2-propen-1-ol

cinnamyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate

cinnamyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide at 20℃; for 4h;98%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

diazomethyl-trimethyl-silane
18107-18-1

diazomethyl-trimethyl-silane

2-[(2,6-dichlorophenyl)amino]phenylacetic acid methyl ester
15307-78-5

2-[(2,6-dichlorophenyl)amino]phenylacetic acid methyl ester

Conditions
ConditionsYield
In methanol; hexane; benzene at 25℃; for 1h;96%
With methanol In Dimethyl ether
methanol
67-56-1

methanol

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

2-[(2,6-dichlorophenyl)amino]phenylacetic acid methyl ester
15307-78-5

2-[(2,6-dichlorophenyl)amino]phenylacetic acid methyl ester

Conditions
ConditionsYield
With sulfuric acid for 0.25h; Reflux;96%
Stage #1: methanol; [2-(2,6-dichloroanilino)phenyl]acetic acid With hydrogenchloride In water for 6h; Reflux;
Stage #2: With sodium carbonate In water
91%
Stage #1: methanol; [2-(2,6-dichloroanilino)phenyl]acetic acid With hydrogenchloride In water for 6h; Reflux;
Stage #2: With sodium hydrogencarbonate In water Cooling with ice; Saturated solution;
91%
1-hydroxy-pyrrolidine-2,5-dione
6066-82-6

1-hydroxy-pyrrolidine-2,5-dione

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

acetic acid N-oxysuccinimide ester
104425-36-7

acetic acid N-oxysuccinimide ester

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In 1,4-dioxane for 8h; Ambient temperature;95%
With dicyclohexyl-carbodiimide In dichloromethane for 1h;90%
With dicyclohexyl-carbodiimide In tetrahydrofuran at 5℃;
Stage #1: 1-hydroxy-pyrrolidine-2,5-dione; [2-(2,6-dichloroanilino)phenyl]acetic acid In tetrahydrofuran at 0 - 5℃; for 0.166667h; Inert atmosphere;
Stage #2: With dicyclohexyl-carbodiimide In tetrahydrofuran at 20℃; Inert atmosphere;
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 20℃; Inert atmosphere;
chlorosulfuric acid chloromethyl ester
49715-04-0

chlorosulfuric acid chloromethyl ester

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

chloromethyl 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate

chloromethyl 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate

Conditions
ConditionsYield
With tetra(n-butyl)ammonium hydrogensulfate; sodium hydrogencarbonate In dichloromethane; water at 20℃; for 1h;95%
With Bu4HSO4 In dichloromethane; water at 20℃; for 1h;
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

(5-methyl-2-phenyl-1,3-dioxan-5-yl)methyl 4-hydroxybenzoate
1528768-73-1

(5-methyl-2-phenyl-1,3-dioxan-5-yl)methyl 4-hydroxybenzoate

(5-methyl-2-phenyl-1,3-dioxan-5-yl)methyl 4-(2-(2-((2,6-dichlorophenyl)amino)phenyl)acetoxy)benzoate
1528768-90-2

(5-methyl-2-phenyl-1,3-dioxan-5-yl)methyl 4-(2-(2-((2,6-dichlorophenyl)amino)phenyl)acetoxy)benzoate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In tetrahydrofuran; dichloromethane at 0 - 20℃; for 18h;95%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

[(2R)-2-aminopropyl]carbamic acid,1,1-dimethylethyl ester
255735-88-7

[(2R)-2-aminopropyl]carbamic acid,1,1-dimethylethyl ester

Boc-propylamide-diclofenac

Boc-propylamide-diclofenac

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 1.5h; Cooling with ice;95%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

1-(2,6-dichlorophenyl)indolin-2-one
15362-40-0

1-(2,6-dichlorophenyl)indolin-2-one

Conditions
ConditionsYield
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 0.5h;94%
With thionyl chloride In dichloromethane; ethyl acetate at 50℃; for 2h; Concentration; Temperature;92%
With hydrogenchloride In acetonitrile at 78.85℃; for 5h; Rate constant; Kinetics; Mechanism; energy data: ΔH(activ.), ΔS(activ.); ΔE(activ.)var. amount of acetonitrile, var. temp.;
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

3-{Methyl{[(nitrosothio)cyclohexyl]methyl}amino)propan-1-ol
306776-45-4

3-{Methyl{[(nitrosothio)cyclohexyl]methyl}amino)propan-1-ol

3-{Methyl{[(nitrosothio)cyclohexyl]methyl}amino)propyl 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate

3-{Methyl{[(nitrosothio)cyclohexyl]methyl}amino)propyl 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 0℃; for 0.5h; Acylation;94%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

diethylamine
109-89-7

diethylamine

diclofenac diethylamine

diclofenac diethylamine

Conditions
ConditionsYield
In acetone at 50 - 55℃; for 2h; pH=8.5 - 10.0;93.7%
2,2-dimethyl-1,3-dioxolane
2916-31-6

2,2-dimethyl-1,3-dioxolane

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

A

1-(2,6-dichlorophenyl)indolin-2-one
15362-40-0

1-(2,6-dichlorophenyl)indolin-2-one

B

5-(2,6-dichloro-phenyl)-6,6-dimethyl-5,9-dihydro-6H-7-oxa-5-aza-benzocyclohepten-8-one

5-(2,6-dichloro-phenyl)-6,6-dimethyl-5,9-dihydro-6H-7-oxa-5-aza-benzocyclohepten-8-one

Conditions
ConditionsYield
With toluene-4-sulfonic acid In ethanol Cyclization;A n/a
B 93%
1-pyrrolidineethanol
2955-88-6

1-pyrrolidineethanol

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

diclofenac epolamine

diclofenac epolamine

Conditions
ConditionsYield
In acetone92%
Magnolol
528-43-8

Magnolol

[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

5,5'-diallyl-2'-hydroxy-[1,1'-biphenyl]-2-yl-2-(2-((2,6-dichlorophenyl)amino)phenyl) acetate

5,5'-diallyl-2'-hydroxy-[1,1'-biphenyl]-2-yl-2-(2-((2,6-dichlorophenyl)amino)phenyl) acetate

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 1h;92%
With dmap In dichloromethane at 25 - 30℃;92%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

2-fluoro-1-phenyl-2-(pyrimidin-2-ylsulfonyl)ethan-1-one

2-fluoro-1-phenyl-2-(pyrimidin-2-ylsulfonyl)ethan-1-one

2-((2,6-dichlorophenyl)amino)phenethyl (Z)-4-((1-fluoro-2-phenyl-2-(pyrimidin-2-yloxy)vinyl)sulfonyl)butanoate

2-((2,6-dichlorophenyl)amino)phenethyl (Z)-4-((1-fluoro-2-phenyl-2-(pyrimidin-2-yloxy)vinyl)sulfonyl)butanoate

Conditions
ConditionsYield
With tetra-(n-butyl)ammonium iodide; N-ethyl-N,N-diisopropylamine In N,N-dimethyl acetamide at 100℃; for 12h; Inert atmosphere; Molecular sieve;92%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

2-ethyl-2-(nitrosothio)butan-1-ol
159982-36-2

2-ethyl-2-(nitrosothio)butan-1-ol

C20H22Cl2N2O3S

C20H22Cl2N2O3S

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 0℃; for 0.5h; Acylation;91%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

ethanolamine
141-43-5

ethanolamine

diclofenac/monoethanolamine

diclofenac/monoethanolamine

Conditions
ConditionsYield
In acetone90%
[2-(2,6-dichloroanilino)phenyl]acetic acid
15307-86-5

[2-(2,6-dichloroanilino)phenyl]acetic acid

2-(2-tert-butyloxycarbonylaminoethoxy)ethanol
139115-91-6

2-(2-tert-butyloxycarbonylaminoethoxy)ethanol

[2-(2,6-dichlorophenylamino)phenyl]acetic acid 2-(2-tert-butoxycarbonylaminoethoxy)ethyl ester
1133407-62-1

[2-(2,6-dichlorophenylamino)phenyl]acetic acid 2-(2-tert-butoxycarbonylaminoethoxy)ethyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 1h;90%
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane for 4h; Cooling with ice;1.166 g
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 0 - 35℃; for 2h;2.44 g

15307-86-5Relevant articles and documents

Isolation and structural characterization of degradation products of aceclofenac by HPLC, HRMS and 2D NMR

Guduru, Santhosh,Anji Karun Mutha,Vijayabhaskar,Kaliyaperumal, Muralidharan,Korupolu, Raghu Babu,Bonige, Kishore Babu,Rumalla, Chidananda Swamy

, p. 851 - 854 (2019)

The stability of aceclofenac under stress conditions was assessed to identify the degradation products. So, it was subjected to stress conditions like acid, base and oxidation, according to ICH guideline Q1A (R2). One degradation product formed when the drug was subjected to acid stress. Three degradation products were formed during the basic stress condition. The drug substance was found to be stable to oxidative stress. The degradants formed during the stress were separated on a C-18 column using gradient preparative HPLC elution. The only product (DP-2) formed during the acid stress and this one is same as of one of the three degradation products (DP-1, DP-2, DP-3) were formed during base stress. 1D and 2D NMR spectra and mass spectral analysis supported the proposed structures for the products. The products DP-2 and DP-3 have been reported earlier but this is the first report of product DP-1 as a degradation product of aceclofenac.

Morpholinoalkyl ester prodrugs of diclofenac: Synthesis, in vitro and in vivo evaluation

Tammara,Narurkar,Crider,Khan

, p. 644 - 648 (1994)

Morpholinoalkyl esters (HCl salts) of diclofenac (1) were synthesized and evaluated in vitro and in vivo for their potential use as prodrugs for oral delivery. Prodrugs were freely soluble in simulated gastric fluid (SGF) and pH 7.4 phosphate buffer and showed a minimum of a 2000-fold increase in solubility over the parent drug. All prodrugs were more lipophilic than 1 as indicated by n-octanol/pH 7.4 buffer partition coefficients, but less lipophilic than 1 in terms of n-octanol/SGF partition coefficients. Potentiometrically determined ionization constants (pK(a)s) were in the range of 7.52 to 8.40 at 25 °C. The chemical and enzymatic hydrolyses of prodrugs were evaluated in SGF/pH 7.4 phosphate buffer and rat plasma, respectively, at 37 °C. All prodrugs were quantitatively hydrolyzed to 1 by either chemical and/or enzymatic means. An increase in carbon chain length rendered the prodrugs more stable at pH 7.4, but less stable in SGF. In general, the esters were hydrolyzed rapidly in rat plasma at 37 °C, the half-lives of hydrolysis being in the range of 4.85 to 23.49 min. Based on in vitro results, prodrug 2 was chosen to evaluate solid-state stability, bioavailability, and in vivo ulcerogenicity. At elevated temperatures, the solid-state decomposition of 2 followed biphasic kinetics, with rapid decomposition occurring initially. The extent, but not the rate, of absorption was significantly greater in rats for prodrug 2 than 1 following single dose oral administration. Prodrug 2 was significantly less irritating to gastric mucosa than 1 following single and chronic oral administration in rats.

Synthesis and spectroscopic/DFT structural characterization of coordination compounds of Nb(V) and Ti(IV) with bioactive carboxylic acids

De Palo, Alice,Biancalana, Lorenzo,Bortoluzzi, Marco,Alessandra Martini, Maria,Marchetti, Fabio,Pampaloni, Guido

, p. 208 - 214 (2018)

The reactions are reported of NbX5 (X = Cl, Br), TiCl4 and Ti(OiPr)4 with a selection of carboxylic acids exhibiting a known biological role, in a chlorinated solvent. The reactions of NbX5 with acetylsalicylic acid (aspirin) proceeded with selective deacetylation of the organic reactant and formation of the salicylate complexes NbX4(C7H5O3) (1a, X = Cl; 1b, X = Br) in 60–65% yields. NbCl5 reacted with diclofenac and ethacrynic acid (EA-CO2H) to give NbCl3[κ3O,O,N-O2CCH2(C6H4)NC6H3Cl2], 2 (80% yield), and NbCl4(O2C-EA), 3 (72% yield), respectively. Ti(OiPr)4 reacted with ethacrynic acid giving Ti(OiPr)2(O2C-EA)2, 4, in 74% yield, as a mixture of two isomers. All the products were characterized by means of analytical and spectroscopic methods, moreover DFT studies were carried out to give insight into structural features.

Stability indicating methods for the determination of aceclofenac

Hasan,Abdel-Elkawy,Elzeany,Wagieh

, p. 91 - 99 (2003)

Five new selective, precise and accurate methods for the determination of aceclofenac in the presence of its degradation product; diclofenac are described. Method A utilizes third derivative spectrophotometry at 242 nm. Method B is RSD1 spectrophotometric method based on the simultaneous use of the first derivative of ratio spectra and measurement at 245 nm. Method C is a pH-induced difference (ΔA) spectrophotometry using UV measurement at 273 nm. Method D is a spectrodensitometric one, which depends on the quantitative densitometric evaluation of thin layer chromatogram of aceclofenac at 275 nm. Method E is RP-HPLC that depends on using methanol: water (60:40 v/v) as mobile phase at a flow rate of 1 ml/min and UV detection at 275 nm. Regression analysis of a beer's plot showed good correlation in the concentration ranges 5-40, 10-40, 15-50, 50-200, 1-50 μg/ml for methods A, B, C, D and E, respectively. These methods are suitable as stability indicating methods for the determination of aceclofenac in presence of its main degradation product, diclofenac. The proposed methods were applied for the analysis of the drug in its pharmaceutical formulation and the results obtained were compared with those obtained with the official B.P. method.

Pd(OH)2/C, a Practical and Efficient Catalyst for the Carboxylation of Benzylic Bromides with Carbon Monoxide

Wakuluk-Machado, Anne-Marie,Dewez, Damien F.,Baguia, Hajar,Imbratta, Miguel,Echeverria, Pierre-Georges,Evano, Gwilherm

, p. 713 - 723 (2020/02/04)

A simple, efficient, cheap, and broadly applicable system for the carboxylation of benzylic bromides with carbon monoxide and water is reported. Upon simple reaction with only 2.5 wt % of Pearlman's catalyst and 10 mol % of tetrabutylammonium bromide in tetrahydrofuran at 110 °C for 4 h, a range of benzylic bromides can be smoothly converted to the corresponding arylacetic acids in good to excellent yields after simple extraction and acid-base wash. The reaction was found to be broadly applicable, scalable, and could be successfully extended to the use of ex situ-generated carbon monoxide and applied to the synthesis of the nonsteroidal anti-inflammatory drug diclofenac.

A diclofenac - glycine - [...], preparation method and application

-

Paragraph 0029; 0030, (2019/06/30)

The invention discloses a diclofenac - glycine - [...], preparation method and application. The conjugate is to glycine as the connecting arm, respectively with the diclofenac and [...]; diclofenac is connected with glycine through amide linkage; diclofenac - glycine conjugate with resveratrol through connected [...] site. Because of the introduction of the glycine, to increase the solubility of the conjugate, diclofenac and resveratrol introduced into the coupling anti- arthritis significantly enhanced, the bad reaction is reduced, the safety is higher; the conjugate synthesis method is simple, and is suitable for industrial production.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 15307-86-5